Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma

Haematologica. 2018 Jan;103(1):e39-e41. doi: 10.3324/haematol.2017.179150. Epub 2017 Nov 2.

Authors

Sophie Voruz¹, Anne Cairoli¹, Olaia Naveiras¹, Laurence de Leval², Edoardo Missiaglia², Krisztian Homicsko³, Olivier Michielin³, Sabine Blum⁴

Affiliations

¹ Service and Central Laboratory of Hematology, University Hospital Lausanne (CHUV), Switzerland.
² Institute of Pathology, University Hospital Lausanne (CHUV), Switzerland.
³ Department of Oncology, CHUV, University Hospital of Lausanne, Switzerland.
⁴ Service and Central Laboratory of Hematology, University Hospital Lausanne (CHUV), Switzerland sabine.blum@chuv.ch.

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biomarkers
Biopsy
Combined Modality Therapy
Histiocytic Sarcoma / diagnosis*
Histiocytic Sarcoma / drug therapy*
Histiocytic Sarcoma / metabolism
Humans
Imatinib Mesylate / administration & dosage
Immunohistochemistry
Immunophenotyping
Male
Molecular Targeted Therapy
Positron Emission Tomography Computed Tomography
Pyridones / administration & dosage
Pyrimidinones / administration & dosage
Retreatment
Symptom Assessment
Treatment Outcome

Substances

Biomarkers
Pyridones
Pyrimidinones
trametinib
Imatinib Mesylate